United States-based Lyndra Therapeutics has collaborated with United States-based Gilead Sciences Inc to develop and commercialise ultra-long-acting oral HIV therapies, it was reported yesterday.
Gilead Sciences Inc will have exclusive rights to Lyndra's therapeutics platform for ultra-long-acting formulations related to HIV. The formulations are claimed to have the potential to improve medication adherence by allowing patients to take a pill once a week, or even less frequently, rather than daily.
Amy Schulman, CEO and co-founder of Lyndra Therapeutics, said, 'Gilead has led the way in HIV prevention and treatment by focusing on reducing pill burden through the development of single-tablet oral regimens for their therapies, addressing an epidemic that affects nearly 40 million people globally. At Lyndra, our commitment to HIV is foundational and we are delighted to continue to work with strong research and development partners such as the Bill & Melinda Gates Foundation and, now, Gilead.'
Gilead joined Lyndra's oversubscribed USD60.9m Series B financing round a few months ago.
Estrella Immunopharma initiates second cohort in EB103 trial for advanced B-cell lymphomas
bioMérieux receives CE-marking for LUMED APSS to support antimicrobial stewardship in Europe
Langhua Pharmaceutical passes US FDA's on-site inspection
Merck reports positive Phase 3 Data on HIV treatment DOR/ISL
QOL Medical's Sucraid shows 81% effectiveness in Congenital Sucrase-Isomaltase Deficiency
Qlucore launches first CE-marked diagnostic test for paediatric leukaemia
Bruker demonstrates advancements in 4D-Proteomics at US HUPO
Mitem Pharma acquires Flisint rights from Sanofi to address rare infectious disease
Audientes partners with Audivista to expand hearing solutions in Middle East and North Africa